NO20041345L - Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse - Google Patents

Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse

Info

Publication number
NO20041345L
NO20041345L NO20041345A NO20041345A NO20041345L NO 20041345 L NO20041345 L NO 20041345L NO 20041345 A NO20041345 A NO 20041345A NO 20041345 A NO20041345 A NO 20041345A NO 20041345 L NO20041345 L NO 20041345L
Authority
NO
Norway
Prior art keywords
suppression
copolymers
methods
autoimmune diseases
autoimmune
Prior art date
Application number
NO20041345A
Other languages
English (en)
Norwegian (no)
Inventor
Jack L Strominger
Masha Fridiks-Hareli
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20041345L publication Critical patent/NO20041345L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
NO20041345A 2001-10-03 2004-03-31 Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse NO20041345L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32670501P 2001-10-03 2001-10-03
PCT/US2002/031399 WO2003029276A2 (fr) 2001-10-03 2002-10-03 Copolymeres destines a la suppression de maladies auto-immunes, et methodes d'utilisation

Publications (1)

Publication Number Publication Date
NO20041345L true NO20041345L (no) 2004-03-31

Family

ID=23273317

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20041345A NO20041345L (no) 2001-10-03 2004-03-31 Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse
NO20041759A NO337092B1 (no) 2001-10-03 2004-04-29 Aminosyrekopolymerer for suppresjon av autoimmunsykdommer, preparat og enhetsdoseform samt deres anvendelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041759A NO337092B1 (no) 2001-10-03 2004-04-29 Aminosyrekopolymerer for suppresjon av autoimmunsykdommer, preparat og enhetsdoseform samt deres anvendelse

Country Status (12)

Country Link
US (3) US7381790B2 (fr)
EP (2) EP1438061B1 (fr)
JP (3) JP5010798B2 (fr)
AU (1) AU2002362445B2 (fr)
CA (1) CA2462459C (fr)
DE (1) DE02800437T1 (fr)
HU (1) HUP0401863A3 (fr)
IL (2) IL161121A0 (fr)
NO (2) NO20041345L (fr)
NZ (1) NZ532199A (fr)
WO (1) WO2003029276A2 (fr)
ZA (1) ZA200402601B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336238A1 (fr) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
WO2002059143A2 (fr) * 2001-01-24 2002-08-01 President And Fellows Of Harvard College Peptides therapeutiques pour troubles de la demyelinisation
EP1725603A2 (fr) * 2004-03-01 2006-11-29 Peptimmune, Inc. Methodes et compositions pour traiter des maladies auto-immunes
WO2005120542A2 (fr) * 2004-05-07 2005-12-22 Peptimmune, Inc. Methodes de traitement de maladie a l'aide de copolymeres aleatoires
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US20090275496A1 (en) * 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP2016095A2 (fr) 2006-04-13 2009-01-21 Peptimmune, Inc. Procédés de conception et de synthèse de compositions de polymères à séquence dirigée par expansion dirigée de la perméabilité épitopique
EP2586460A1 (fr) 2007-10-16 2013-05-01 Peptimmune, Inc. Procédé de conception et de préparation de vaccins comprenant une composition polymère à séquence dirigée par expansion dirigée d'épitopes
WO2009075854A2 (fr) * 2007-12-10 2009-06-18 Peptimmune Inc. Quantification efficace de mélanges de peptides complexes dans des échantillons de tissus et procédés thérapeutiques améliorés
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
BR112012016459B1 (pt) * 2010-01-04 2020-01-14 Mapi Pharma Ltd composto farmacêutico parenteral de ação prolongada, composição farmacêutica e sal de glatirâmero farmaceuticamente aceitável
EP2699317B1 (fr) 2011-04-21 2016-08-10 Mapi Pharma Limited Pentapolymère statistique pour le traitement de maladies auto-immunes
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
NZ725006A (en) 2014-03-12 2019-11-29 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3170836B1 (fr) * 2015-11-23 2018-10-24 Chemi SPA Analyse rp-hplc de mélanges de polypeptides complexes
EP3478316A1 (fr) * 2016-07-01 2019-05-08 Declion Holdings LLC Composés d'amino acides de copolymères et leurs applications.
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2022103673A2 (fr) 2020-11-10 2022-05-19 Fridkis Hareli Masha Compositions de peptides aléatoires d'épitope incorporés (eerp) pour le traitement d'états à médiation immunitaire, et procédés d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3052655A (en) * 1958-08-01 1962-09-04 Sidney W Fox Thermal polymerization of amino acid mixtures containing aspartic acid or a thermal precursor of aspartic acid
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4996292A (en) * 1989-06-30 1991-02-26 Fox Sidney W Self-sealing artificial skin comprising copoly-alpha-amino acid
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
NZ333946A (en) 1996-08-05 2000-09-29 Harvard College MHC binding peptide oligomers
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
IL138647A0 (en) 1998-03-23 2001-10-31 Harvard College Synthesis of compounds and libraries of compounds
CA2337688C (fr) * 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Traitement de maladies auto-immunes a l'aide du copolymere 1 et copolymeres associes
CA2336238A1 (fr) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
PT2090583E (pt) * 1998-09-25 2011-09-14 Yeda Res & Dev Polipéptidos relacionados com o copolímero 1 para utilização a título de marcadores de massas moleculares e em terapêutica
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
WO2002059143A2 (fr) 2001-01-24 2002-08-01 President And Fellows Of Harvard College Peptides therapeutiques pour troubles de la demyelinisation
AU2002317071B2 (en) * 2001-06-22 2008-01-31 The Hospital For Sick Children Antimicrobial peptides
US8017166B2 (en) 2004-11-01 2011-09-13 Steven Amory Twitty Method of producing stackable low-fat snack chips

Also Published As

Publication number Publication date
JP5010798B2 (ja) 2012-08-29
EP1438061A2 (fr) 2004-07-21
JP2005511518A (ja) 2005-04-28
HUP0401863A3 (en) 2012-09-28
EP1438061A4 (fr) 2005-02-23
US8017125B2 (en) 2011-09-13
ZA200402601B (en) 2005-07-27
NO20041759L (no) 2004-04-29
CA2462459A1 (fr) 2003-04-10
IL161121A (en) 2010-11-30
US7381790B2 (en) 2008-06-03
CA2462459C (fr) 2007-12-18
HUP0401863A2 (hu) 2004-12-28
US20110286959A1 (en) 2011-11-24
WO2003029276A3 (fr) 2003-11-27
US20040038887A1 (en) 2004-02-26
NZ532199A (en) 2008-02-29
EP1438061B1 (fr) 2016-05-11
EP2123669A1 (fr) 2009-11-25
DE02800437T1 (de) 2004-11-11
IL161121A0 (en) 2004-08-31
US20080241099A1 (en) 2008-10-02
NO337092B1 (no) 2016-01-18
US9028835B2 (en) 2015-05-12
WO2003029276A2 (fr) 2003-04-10
JP2009185057A (ja) 2009-08-20
AU2002362445B2 (en) 2006-09-21
JP5525749B2 (ja) 2014-06-18
JP2012162545A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
NO20041345L (no) Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse
AU2003299509A8 (en) Crosslinked compounds and methods of making and using thereof
EP1545468A4 (fr) Preparations d'opioides a liberation soutenue et methodes d'utilisation
IL161258A0 (en) Heterocyclic compounds and methods of use
AU6118001A (en) Combination therapeutic compositions and methods of use
GB2393202B (en) Methods of well treatment
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
AU2002359512A8 (en) Belts and methods of use thereof
AU2003243298A1 (en) Gaming device and methods of use
PL364111A1 (en) Methods of treating inflammatory and immune diseases using inhibitors of ikappab kinase (ikk)
DE60208700D1 (de) Schälgerät und zugehörige verfahren
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
NO20041968L (no) Anvendelse av cystationin
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
IL148202A0 (en) Copolymers and methods of treating prion-related diseases
EP1416795A4 (fr) Compositions et procedes pour le traitement de maladies mitochondriales
GB0200260D0 (en) Microparticles and methods of making them
EP1472273A4 (fr) Compositions et methodes de traitement de maladies d'origine immune
GB0324523D0 (en) Compositions and methods of treatment
AU2003270815A8 (en) Treatment of irritable bowel syndrome and related bowel diseases
EP1416889A4 (fr) Lentille a incision reduite et utilisation de celle-ci
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
IL162481A0 (en) Method and use of determining genotype

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application